Braskem SA
BOVESPA:BRKM5
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
14.35
27.42
|
Price Target |
|
We'll email you a reminder when the closing price reaches BRL.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Braskem SA
Cost of Revenue
Braskem SA
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Braskem SA
BOVESPA:BRKM5
|
Cost of Revenue
-R$70.9B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
||
Dexxos Participacoes SA
BOVESPA:DEXP3
|
Cost of Revenue
-R$1.4B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
Braskem SA
Glance View
Braskem SA engages in the manufacture of petrochemicals and other related products. The company is headquartered in Camacari, Bahia. The firm's activities are divided into three operational segments: Brazil; the United States and Europe; and Mexico. The Brazil segment is focused on the production of polyethylene (PE), polypropylene (PP) and polyvinylchloride (PVC) resins, in addition to basic chemical inputs such as ethylene, propylene, butadiene, benzene, toluene, chlorine, soda, and solvents, among others. The United States and Europe segment is responsible for the production of polypropylene in units in the United States and Germany. The Mexico segment consists of the operation of ethylene cracker and polyethylene units located in Mexico.
See Also
What is Braskem SA's Cost of Revenue?
Cost of Revenue
-70.9B
BRL
Based on the financial report for Sep 30, 2023, Braskem SA's Cost of Revenue amounts to -70.9B BRL.
What is Braskem SA's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-7%
Over the last year, the Cost of Revenue growth was 19%. The average annual Cost of Revenue growth rates for Braskem SA have been -17% over the past three years , -11% over the past five years , and -7% over the past ten years .